JP2016521556A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016521556A5 JP2016521556A5 JP2016518041A JP2016518041A JP2016521556A5 JP 2016521556 A5 JP2016521556 A5 JP 2016521556A5 JP 2016518041 A JP2016518041 A JP 2016518041A JP 2016518041 A JP2016518041 A JP 2016518041A JP 2016521556 A5 JP2016521556 A5 JP 2016521556A5
- Authority
- JP
- Japan
- Prior art keywords
- oligonucleotide
- nucleotide
- nucleotides
- composition
- stranded oligonucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361832677P | 2013-06-07 | 2013-06-07 | |
| US61/832,677 | 2013-06-07 | ||
| PCT/US2014/041345 WO2014197826A1 (en) | 2013-06-07 | 2014-06-06 | Compositions and methods for modulating foxp3 expression |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016521556A JP2016521556A (ja) | 2016-07-25 |
| JP2016521556A5 true JP2016521556A5 (enExample) | 2017-07-20 |
Family
ID=52008624
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016518041A Pending JP2016521556A (ja) | 2013-06-07 | 2014-06-06 | Ｆｏｘｐ３発現を調節するための組成物及び方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20160122760A1 (enExample) |
| EP (1) | EP3004354A4 (enExample) |
| JP (1) | JP2016521556A (enExample) |
| KR (1) | KR20160027968A (enExample) |
| AU (1) | AU2014274730A1 (enExample) |
| CA (1) | CA2914536A1 (enExample) |
| WO (1) | WO2014197826A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201492121A1 (ru) | 2012-05-16 | 2015-10-30 | Рана Терапьютикс, Инк. | Композиции и способы для модулирования экспрессии семейства генов гемоглобина |
| SG11201407486PA (en) | 2012-05-16 | 2014-12-30 | Rana Therapeutics Inc | Compositions and methods for modulating utrn expression |
| AU2013262709A1 (en) | 2012-05-16 | 2015-01-22 | Rana Therapeutics, Inc. | Compositions and methods for modulating MECP2 expression |
| KR20150030205A (ko) | 2012-05-16 | 2015-03-19 | 라나 테라퓨틱스, 인크. | Smn 유전자 패밀리 발현을 조절하기 위한 조성물 및 방법 |
| JP2015523853A (ja) | 2012-05-16 | 2015-08-20 | ラナ セラピューティクス インコーポレイテッド | Ａｔｐ２ａ２発現を調節するための組成物及び方法 |
| US10837014B2 (en) | 2012-05-16 | 2020-11-17 | Translate Bio Ma, Inc. | Compositions and methods for modulating SMN gene family expression |
| EP3033422A4 (en) | 2013-08-16 | 2017-08-02 | Rana Therapeutics Inc. | Oligonucleotides targeting euchromatin regions of genes |
| US9855270B2 (en) * | 2014-03-13 | 2018-01-02 | Genentech, Inc. | Methods and compositions for modulating estrogen receptor mutants |
| WO2017181026A1 (en) * | 2016-04-15 | 2017-10-19 | Translate Bio Ma, Inc. | Selective modulation of foxp3 expression |
| WO2017184082A1 (en) * | 2016-04-22 | 2017-10-26 | Nanyang Technological University | A lymphocyte permeating chimeric oligonucleotide, methods and uses thereof |
| WO2018031871A1 (en) * | 2016-08-12 | 2018-02-15 | Translate Bio Ma, Inc. | Ex vivo modulation of foxp3 expression |
| US11584932B2 (en) | 2016-11-01 | 2023-02-21 | The Research Foundation For The State University Of New York | 5-halouracil-modified microRNAs and their use in the treatment of cancer |
| AU2017368050A1 (en) | 2016-11-29 | 2019-06-20 | Puretech Lyt, Inc. | Exosomes for delivery of therapeutic agents |
| US12024715B2 (en) * | 2017-11-07 | 2024-07-02 | Temple University-Of The Commonwealth System Of Higher Education | Compositions and methods for improved T cells |
| AU2019347849B2 (en) * | 2018-09-26 | 2025-08-28 | AUM LifeTech, Inc. | 2'FANA modified Foxp3 antisense oligonucleotides and methods of use thereof |
| TW202028222A (zh) * | 2018-11-14 | 2020-08-01 | 美商Ionis製藥公司 | Foxp3表現之調節劑 |
| CN111378622B (zh) * | 2018-12-29 | 2022-12-02 | 华东师范大学 | 核酸编码的car-t细胞及其制备方法和应用 |
| EP3918073A4 (en) * | 2019-01-29 | 2023-11-22 | Ionis Pharmaceuticals, Inc. | COMPOUNDS AND METHODS FOR REDUCING APP EXPRESSION |
| WO2020212567A1 (en) * | 2019-04-18 | 2020-10-22 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of usher syndrome |
| US11866708B2 (en) * | 2019-10-22 | 2024-01-09 | Board Of Regents, The University Of Texas System | Tailored modulation of gene regulation programs via functional enhancer RNA |
| WO2021262919A2 (en) | 2020-06-26 | 2021-12-30 | The Research Foundation For The State University Of New York | 5-halouracil-modified micrornas and their use in the treatment of cancer |
| KR20230043914A (ko) | 2020-07-28 | 2023-03-31 | 아이오니스 파마수티컬즈, 인코포레이티드 | App 발현을 감소시키기 위한 화합물 및 방법 |
| WO2022088342A1 (zh) * | 2020-10-28 | 2022-05-05 | 苏州吉玛基因股份有限公司 | 一种靶向FOXP3基因的siRNA及其修饰方法 |
| JP2024523363A (ja) * | 2021-06-18 | 2024-06-28 | アイオーニス ファーマシューティカルズ， インコーポレーテッド | Ｉｆｎａｒ１の発現を低減するための化合物及び方法 |
| WO2023235838A2 (en) * | 2022-06-02 | 2023-12-07 | Skyhawk Therapeutics, Inc. | Rna-targeting splicing modifiers for treatment of foxp3-associated conditions and diseases |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US14008A (en) * | 1856-01-01 | Improvement in furnaces for soldering | ||
| ATE405586T1 (de) * | 2001-05-08 | 2008-09-15 | Darwin Molecular Corp | Verfahren zur regulierung der immunfunktion in primaten unter verwendung des foxp3-proteins |
| US8029985B2 (en) * | 2004-09-01 | 2011-10-04 | Vybion, Inc. | Amplified bioassay |
| US8629108B2 (en) * | 2006-06-27 | 2014-01-14 | Opexa Therapeutics, Inc. | Rheumatoid arthritis T cell vaccine |
| EP2064350B1 (en) * | 2006-11-27 | 2013-01-02 | Ludwig Institute for Cancer Research Ltd. | Expression of foxp3 by cancer cells |
| WO2008103761A2 (en) * | 2007-02-20 | 2008-08-28 | Sequenom, Inc. | Methods and compositions for cancer diagnosis and treatment based on nucleic acid methylation |
| WO2008141282A2 (en) * | 2007-05-11 | 2008-11-20 | The Regents Of The University Of Michigan | Materials and methods for foxp3 tumor suppression |
| US20120004278A1 (en) * | 2010-06-18 | 2012-01-05 | The Board Of Trustees Of The Leland Stanford Junior University | Linc rnas in cancer diagnosis and treatment |
| US20130122046A1 (en) * | 2010-07-09 | 2013-05-16 | Institut Pasteur Of Shanghai, Cas | Regulatory factor of foxp3 and regulatory t cells and use thereof |
| WO2012020839A1 (ja) * | 2010-08-12 | 2012-02-16 | 塩野義製薬株式会社 | 癌治療用医薬組成物 |
| AU2011298987B2 (en) * | 2010-09-10 | 2017-09-28 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
| US9920317B2 (en) * | 2010-11-12 | 2018-03-20 | The General Hospital Corporation | Polycomb-associated non-coding RNAs |
| WO2012075114A2 (en) * | 2010-12-01 | 2012-06-07 | Ablitech, Inc. | Nucleic acid-polymer conjugates and uses thereof |
| BR112014028647A2 (pt) * | 2012-05-16 | 2017-07-25 | Rana Therapeutics Inc | composições e métodos para modulação da expressão de bdnf |
| CN104583398A (zh) * | 2012-05-16 | 2015-04-29 | Rana医疗有限公司 | 用于调节基因表达的组合物和方法 |
| EP2850183A4 (en) * | 2012-05-16 | 2016-02-10 | Rana Therapeutics Inc | COMPOSITIONS AND METHOD FOR MODULATING GENE EXPRESSION |
| US9567581B2 (en) * | 2012-08-07 | 2017-02-14 | The General Hospital Corporation | Selective reactivation of genes on the inactive X chromosome |
-
2014
- 2014-06-06 WO PCT/US2014/041345 patent/WO2014197826A1/en not_active Ceased
- 2014-06-06 US US14/896,537 patent/US20160122760A1/en not_active Abandoned
- 2014-06-06 CA CA2914536A patent/CA2914536A1/en not_active Abandoned
- 2014-06-06 EP EP14807355.4A patent/EP3004354A4/en not_active Withdrawn
- 2014-06-06 JP JP2016518041A patent/JP2016521556A/ja active Pending
- 2014-06-06 AU AU2014274730A patent/AU2014274730A1/en not_active Abandoned
- 2014-06-06 KR KR1020167000349A patent/KR20160027968A/ko not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016522674A5 (enExample) | ||
| JP2015518710A5 (enExample) | ||
| JP2015523853A5 (enExample) | ||
| JP2015518712A5 (enExample) | ||
| JP2015518713A5 (enExample) | ||
| JP2015519057A5 (enExample) | ||
| JP2015523855A5 (enExample) | ||
| JP2015518711A5 (enExample) | ||
| JP2015523854A5 (enExample) | ||
| EP4455285A3 (en) | Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof | |
| HRP20201200T1 (hr) | OLIGONUKLEOTIDNI SPOJEVI ZA CILJANJE HUNTINGTIN mRNK | |
| HRP20210612T1 (hr) | Postupci i pripravci za specifičnu inhibiciju glikolat oksidaze (hao1) pomoću dvolančane rnk | |
| JP2014527401A5 (enExample) | ||
| JP2016502858A5 (enExample) | ||
| JP2016116520A5 (enExample) | ||
| RU2020108189A (ru) | Композиции и способы лечения бокового амиотрофического склероза (als) | |
| HRP20220379T1 (hr) | Antisense oligonukleotidi korisni u liječenju pompeove bolesti | |
| JP2016520310A5 (enExample) | ||
| JP2018529732A5 (enExample) | ||
| JP2008523094A5 (enExample) | ||
| EP2470656A1 (en) | Composition for inhibiting gene expression and uses thereof | |
| RU2014147563A (ru) | КОМПОЗИЦИИ i-PHK ДЛЯ СЕРПИНА C1 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| JP2011256204A5 (enExample) | ||
| RU2015155332A (ru) | Олигонуклеотидные модуляторы в-клеточной cll/лимфомы 11а (bcl11а) и их применение | |
| JP2022511550A5 (enExample) |